Skip to main content
SpringerLink
Log in

Personalized Neurology

  • Chapter
  • First Online:
Applications of Biotechnology in Neurology

  • 1320 Accesses

Abstract

Personalized medicine, also referred to as individualized therapy, simply means the prescription of specific treatments and therapeutics best suited for an individual taking into consideration both genetic and environmental factors that influence response to therapy. Genomic/proteomic technologies have facilitated the development of personalized medicines but other technologies such as metabolomics are also contributing to this effort. Personalized medicine is the best way to integrate new biotechnologies into medicine for improving the understanding of pathomechanism of diseases and management of patients (Jain 2009). Relationship of various technologies to personalized medicine is shown in Fig. 18.1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adalbert R, Nogradi A, Babetto E, et al. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 2009;132(Pt 2):402–16.

    PubMed  Google Scholar 

  • Babic T, Lakusic DM, Sertic J, et al. ApoE genotyping and response to galanthamine in Alzheimer’s disease – a real life retrospective study. Coll Antropol 2004;28:199–204.

    PubMed  CAS  Google Scholar 

  • Beier D, Röhrl S, Pillai DR, et al. Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma. Cancer Res 2008;68:5706–15.

    Article  PubMed  CAS  Google Scholar 

  • Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270–81.

    Article  PubMed  CAS  Google Scholar 

  • Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011;10:702–9.

    Article  PubMed  Google Scholar 

  • Billeci AM, Agnelli G, Caso V. Stroke pharmacogenomics. Expert Opin Pharmacother 2009;10:2947–57.

    Article  PubMed  CAS  Google Scholar 

  • Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009;326:1509–12.

    Article  PubMed  CAS  Google Scholar 

  • Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta -amyloid precursor protein converting enzyme 1. J Biol Chem 2008;284:1971–81.

    Article  PubMed  Google Scholar 

  • Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008;28 Suppl 2:21–7.

    Article  PubMed  Google Scholar 

  • Byun E, Caillier SJ, Montalban X, et al. Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. Arch Neurol 2008;65:337–44.

    Article  PubMed  Google Scholar 

  • Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Mini Rev Med Chem 2002;2:59–84.

    Article  PubMed  CAS  Google Scholar 

  • Cacabelos R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics 2003;4:597–622.

    Article  PubMed  CAS  Google Scholar 

  • Chasman DI, Schürks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011;43:695–8.

    Article  PubMed  CAS  Google Scholar 

  • Chen P, Lin JJ, Lu CS, et al. Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan. N Engl J Med 2011;364:1126–133.

    Article  PubMed  CAS  Google Scholar 

  • Colman H, Zhang L, Sulman EP, et al., A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010;12:49–57.

    Article  PubMed  CAS  Google Scholar 

  • Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009;132:2517–30.

    Article  PubMed  CAS  Google Scholar 

  • de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes and Development 2008;22:449–62.

    Article  PubMed  Google Scholar 

  • Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105:5213–18.

    Article  PubMed  CAS  Google Scholar 

  • Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet 2011;7:e1002141.

    Article  PubMed  CAS  Google Scholar 

  • Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer’s disease risk. Cell 2008;133:1149–61.

    Article  PubMed  CAS  Google Scholar 

  • Fenton TR, Nathanson D, Ponte de Albuquerque C, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. PNAS 2012;109:14164–9.

    Google Scholar 

  • Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011;77:1551–60.

    Article  PubMed  CAS  Google Scholar 

  • Frost JJ. Molecular imaging to biomarker development in neuroscience. Ann N Y Acad Sci 2008;1144:251–5.

    Article  PubMed  Google Scholar 

  • Galas DJ, Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. IBC 2009;1:6.

    Google Scholar 

  • Gentile G, Borro M, Simmaco M, Missori S, Lala N, Martelletti P. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug Metab Toxicol 2011;7:39–47.

    Article  PubMed  CAS  Google Scholar 

  • Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature 2009;461:908–15.

    Article  PubMed  CAS  Google Scholar 

  • Greenberg DA, Cayanis E, Strug L, et al. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 2005;76:139–46.

    Article  PubMed  CAS  Google Scholar 

  • Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics 2007;17:657–66.

    Article  PubMed  CAS  Google Scholar 

  • Habek M, Borovecki F, Brinar VV. Genomics in multiple sclerosis. Clin Neurol Neurosurg 2010;112:621–4.

    Article  PubMed  Google Scholar 

  • Hecker M, Goertsches RH, Fatum C, et al. Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment. Pharmacogenomics J 2012;12:134–46.

    Article  PubMed  CAS  Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. NEJM 2005;352:997–1003.

    Article  PubMed  CAS  Google Scholar 

  • Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 2008;9:638–46.

    Article  PubMed  CAS  Google Scholar 

  • Hongo J, Nakaaki S, Shinagawa Y, et al. SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008;26:556–66.

    Article  PubMed  CAS  Google Scholar 

  • Intergroup Radiation Therapy Oncology Group Trial 9402; Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707–14.

    Google Scholar 

  • International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214–9.

    Google Scholar 

  • Jain KK. Personalized neurology. Personal Med 2005;1:15–21.

    Article  Google Scholar 

  • Jain KK. Textbook of Personalized Medicine. New York: Springer, 2009.

    Book  Google Scholar 

  • Jain KK. Personalized Clinical Laboratory Diagnostics. Adv Clin Chem 2009a;47:95–119.

    Article  PubMed  CAS  Google Scholar 

  • Jain KK. Donepezil. In, Gilman S (ed) Medlink Neurology, 2012, Medlink Corporation, San Diego, California (http://www.medlink.com/)

  • Jain KK. Synthetic biology and personalized medicine. Med Princ & Pract 2012a Aug 16;doi:10.1159/000341794.

  • Jain KK. DNA Sequencing: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland, 2012b.

    Google Scholar 

  • Jain KK. Alzheimer’s Disease: drugs, markets and companies. Jain PharmaBiotech, Basel, Switzerland, 2012c.

    Google Scholar 

  • Jain KK. RNAi: Technologies, Companies & Markets. Jain PharmaBiotech Publications, Basel, 2012d.

    Google Scholar 

  • Jones DT, Jäger N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488:100–5.

    Article  PubMed  CAS  Google Scholar 

  • Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012;488:96–9.

    Article  PubMed  CAS  Google Scholar 

  • Kanetaka H, Hanyu H, Hirao K, et al. Prediction of response to donepezil in Alzheimer’s disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion. Nucl Med Commun 2008;29:568–73.

    Article  PubMed  CAS  Google Scholar 

  • Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389–97.

    Article  PubMed  CAS  Google Scholar 

  • Kretschmar C, Kleinberg L, Greenberg M, et al. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2007;48:285–91.

    Article  PubMed  CAS  Google Scholar 

  • Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008;18:989–98.

    Article  PubMed  CAS  Google Scholar 

  • Kwan P, Schachter SC, Brodie MJ. Drug-Resistant Epilepsy. N Engl J Med 2011;365:919–26.

    Article  PubMed  CAS  Google Scholar 

  • Lee MT, Hung SI, Wei CY, Chen YT. Pharmacogenetics of toxic epidermal necrolysis. Expert Opin Pharmacother 2010;11:2153–62.

    Article  PubMed  CAS  Google Scholar 

  • Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391–7.

    Article  PubMed  CAS  Google Scholar 

  • Long JM, Lahiri DK. MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun 2011;404:889–95.

    Article  PubMed  CAS  Google Scholar 

  • Loup F, Picard F, Yonekawa Y, et al. Selective changes in GABAA receptor subtypes in white matter neurons of patients with focal epilepsy. Brain 2009;132:2449–63.

    Article  PubMed  Google Scholar 

  • Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation. Brain Res 2002;953:135–43.

    Article  PubMed  Google Scholar 

  • Martinez-Forero I, Pelaez A, Villoslada P. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother 2008;9:3053–67.

    Article  PubMed  CAS  Google Scholar 

  • McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. N Engl J Med 2011;364:1134–43.

    Article  PubMed  CAS  Google Scholar 

  • Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. NEJM 2005; 353:2012–24.

    Article  PubMed  CAS  Google Scholar 

  • Nielsen J. Translational and systems medicine. J Int Med 2012;271:108–10.

    Article  CAS  Google Scholar 

  • Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408–14.

    Article  PubMed  Google Scholar 

  • Pallud J, Taillandier L, Capelle L, et al. Quantitative Morphological MRI Follow-up of Low-grade Glioma: A Plead for Systematic Measurement of Growth Rates. Neurosurgery 2012;71:729–40.

    Article  PubMed  Google Scholar 

  • Park S, Hatanpaa KJ, Xie Y, et al. The Receptor Interacting Protein 1 Inhibits p53 Induction through NF-{kappa}B Activation and Confers a Worse Prognosis in Glioblastoma. Cancer Res 2009;69:2809–16.

    Article  PubMed  CAS  Google Scholar 

  • Patel N, Hoang D, Miller N, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener 2008;3:10.

    Article  PubMed  Google Scholar 

  • Piane M, Lulli P, Farinelli I, et al. Genetics of migraine and pharmacogenomics: some considerations. J Headache Pain 2007;8:334–9.

    Article  PubMed  CAS  Google Scholar 

  • Potkin SG, Guffanti G, Lakatos A, et al. Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer’s Disease. PLoS ONE 2009;4:e6501.

    Article  PubMed  Google Scholar 

  • Rafei M, Hsieh J, Zehntner S, et al. A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009;15:1038–45.

    Article  PubMed  CAS  Google Scholar 

  • Ragozzino D, Palma E, Di Angelantonio S, et al. Rundown of GABA type A receptors is a ­dysfunction associated with human drug-resistant mesial temporal lobe epilepsy. PNAS 2005;102:15219–23.

    Article  PubMed  CAS  Google Scholar 

  • Reiman EM, Webster JA, Myers AJ, et al. GAB2 Alleles Modify Alzheimer’s Risk in APOE varepsilon4 Carriers. Neuron 2007;54:713–20.

    Article  PubMed  CAS  Google Scholar 

  • Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168–77.

    Article  PubMed  CAS  Google Scholar 

  • Rozzini L, Chilovi BV, Bertoletti E, et al. Serum albumin level interferes with the effect of donepezil in Alzheimer’s disease. Aging Clin Exp Res 2008;20:509–12.

    PubMed  CAS  Google Scholar 

  • Rudin CM, Hann CL, Laterra J, et al. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. NEJM 2009;361:1173–8.

    Article  PubMed  CAS  Google Scholar 

  • Schürks M, Kurth T, Stude P, et al. G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther 2007;82:396–401.

    Article  PubMed  Google Scholar 

  • Siddiqui A, Kerb R, Weale ME, et al. Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1. NEJM 2003;348:1442–8.

    Article  PubMed  CAS  Google Scholar 

  • Smith AK, White PD, Aslakson E, et al. Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006;7:387–94.

    Article  PubMed  CAS  Google Scholar 

  • Smith P, Al Hashimi A, Girard J, et al. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 2011;116:240–7.

    Article  PubMed  CAS  Google Scholar 

  • Stamatakos GS, Antipas VP, Uzunoglu NK. Simulating chemotherapeutic schemes in the individualized treatment context: The paradigm of glioblastoma multiforme treated by temozolomide in vivo. Comput Biol Med 2006;36:1216–34.

    Article  PubMed  CAS  Google Scholar 

  • Tang Y, Glauser TA, Gilbert DL, et al.: Valproic acid blood genomic expression patterns in children with epilepsy – a pilot study. Acta Neurol Scand 2004;109:159–68.

    Article  PubMed  CAS  Google Scholar 

  • Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS 2005;102:5507–12.

    Article  PubMed  CAS  Google Scholar 

  • Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Exp Opin Pharmacother 2007;8:1441–9.

    Article  CAS  Google Scholar 

  • Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol 2010;641:82–7.

    Article  PubMed  CAS  Google Scholar 

  • Tfelt-Hansen P, Brøsen K. Pharmacogenomics and migraine: possible implications. J Headache Pain 2008;9:13–8.

    Article  PubMed  Google Scholar 

  • van Baarsen LG, Vosslamber S, Tijssen M, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008;3:e1927.

    Article  PubMed  Google Scholar 

  • Vernon SD, Reeves WC. The challenge of integrating disparate high-content data: epidemiological, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics 2006;7:345–54.

    Article  PubMed  Google Scholar 

  • Vilardo E, Barbato C, Ciotti M, et al. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem 2010;285:18344–51.

    Article  PubMed  CAS  Google Scholar 

  • Vosslamber S, van Baarsen LG, Verweij CL. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics 2009;10:97–108.

    Article  PubMed  CAS  Google Scholar 

  • Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13:887–95.

    Article  PubMed  CAS  Google Scholar 

  • Yang X, Zhou J, Weidong C, et al. 14-3-3zeta positive expression is associated with a poor prognosis in patients with Glioblastoma. Neurosurgery 2011;68:932–8.

    PubMed  Google Scholar 

  • Yasuda CL, Cendes F. Neuroimaging for the prediction of response to medical and surgical treatment in epilepsy. Expert Opin Med Diagn 2012 June 6; doi: 10.1517/17530059.2012.683408.

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Basel, Switzerland

    Kewal K. Jain MD, FRACS, FFPM

Authors
  1. Kewal K. Jain MD, FRACS, FFPM
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jain, K.K. (2013). Personalized Neurology. In: Applications of Biotechnology in Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-272-8_18

Download citation

Publish with us

Policies and ethics

Search

Navigation